1. Home
  2. THCH vs CABA Comparison

THCH vs CABA Comparison

Compare THCH & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TH International Limited Ordinary shares

THCH

TH International Limited Ordinary shares

HOLD

Current Price

$2.20

Market Cap

85.5M

Sector

Finance

ML Signal

HOLD

Logo Cabaletta Bio Inc.

CABA

Cabaletta Bio Inc.

HOLD

Current Price

$2.19

Market Cap

227.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
THCH
CABA
Founded
2018
2017
Country
China
United States
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
85.5M
227.2M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
THCH
CABA
Price
$2.20
$2.19
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$13.50
AVG Volume (30 Days)
11.0K
2.1M
Earning Date
12-09-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$188,274,078.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.95
$0.99
52 Week High
$3.82
$3.67

Technical Indicators

Market Signals
Indicator
THCH
CABA
Relative Strength Index (RSI) 38.83 40.92
Support Level $2.10 $2.32
Resistance Level $2.29 $2.49
Average True Range (ATR) 0.10 0.13
MACD -0.02 -0.02
Stochastic Oscillator 25.00 12.07

Price Performance

Historical Comparison
THCH
CABA

About THCH TH International Limited Ordinary shares

TH International Ltd is the parent company of the franchise of Tim Hortons coffee shops and has the rights to operate Tim Hortons coffee shops in mainland China, Hong Kong, and Macau. Through the Tim Hortons brand, the firm offers freshly brewed coffee, tea, and other beverages, bakery & sides, and sandwiches. The Company operated under single reportable segment, Tim Hortons. The company's revenue is derived from its operations in the PRC.

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.

Share on Social Networks: